Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies

摘要: Anti-EGF receptor (EGFR) antibodies (cetuximab and panitumumab) have been demonstrated to be efficient in the treatment of metastatic colorectal cancer. However, these costly potentially toxic treatments are active a subset patients, which renders necessary identification factors that able better define patients will benefit from treatments. Advances understanding signaling pathways inhibited by targeted therapies led KRAS mutations as strong predictor resistance anti-EGFR therapies. Other molecular markers, involved EGF pathway or antibody dependent cell-mediated cytotoxicity-related anti-tumor effect therapies, also interesting evaluated future clinical trials.